2017 Q1 Form 10-Q Financial Statement
#000143774917009251 Filed on May 15, 2017
Income Statement
| Concept | 2017 Q1 | 2016 Q1 |
|---|---|---|
| Revenue | $149.6K | $269.3K |
| YoY Change | -44.47% | 27.97% |
| Cost Of Revenue | $55.14K | $73.18K |
| YoY Change | -24.65% | 24.42% |
| Gross Profit | $94.43K | $196.1K |
| YoY Change | -51.86% | 29.35% |
| Gross Profit Margin | 63.13% | 72.83% |
| Selling, General & Admin | ||
| YoY Change | ||
| % of Gross Profit | ||
| Research & Development | $260.3K | $310.0K |
| YoY Change | -16.01% | -51.16% |
| % of Gross Profit | 275.71% | 158.03% |
| Depreciation & Amortization | $6.120K | $836.00 |
| YoY Change | 632.06% | -9.62% |
| % of Gross Profit | 6.48% | 0.43% |
| Operating Expenses | $715.1K | $885.6K |
| YoY Change | -19.26% | -30.73% |
| Operating Profit | -$620.6K | -$689.5K |
| YoY Change | -9.98% | -38.82% |
| Interest Expense | $192.7K | $234.4K |
| YoY Change | -17.78% | 195.46% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $127.1K | -$1.035M |
| YoY Change | -112.28% | 3112.62% |
| Pretax Income | ||
| YoY Change | ||
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$493.5K | -$1.725M |
| YoY Change | -71.38% | 48.78% |
| Net Earnings / Revenue | -329.97% | -640.34% |
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | ||
| COMMON SHARES | ||
| Basic Shares Outstanding | 96.00M | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2017 Q1 | 2016 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $100.0K | $600.0K |
| YoY Change | -83.33% | -75.51% |
| Cash & Equivalents | $97.54K | $604.1K |
| Short-Term Investments | ||
| Other Short-Term Assets | $120.0K | $150.0K |
| YoY Change | -20.0% | 0.0% |
| Inventory | $202.9K | $258.5K |
| Prepaid Expenses | $115.4K | $147.5K |
| Receivables | $451.4K | $46.03K |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $867.2K | $1.056M |
| YoY Change | -17.9% | -64.08% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $70.82K | $3.392K |
| YoY Change | 1987.79% | -66.08% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | $230.1K | |
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $13.84K | $11.19K |
| YoY Change | 23.68% | 11.91% |
| Total Long-Term Assets | $84.66K | $244.7K |
| YoY Change | -65.4% | -55.52% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $867.2K | $1.056M |
| Total Long-Term Assets | $84.66K | $244.7K |
| Total Assets | $951.8K | $1.301M |
| YoY Change | -26.83% | -62.73% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $1.033M | $356.2K |
| YoY Change | 190.07% | 78.12% |
| Accrued Expenses | $546.8K | $252.0K |
| YoY Change | 116.99% | -50.59% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $100.0K | $5.450M |
| YoY Change | -98.17% | 1.49% |
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $8.220M | $6.655M |
| YoY Change | 23.52% | 7.51% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | ||
| YoY Change | ||
| Total Long-Term Liabilities | $0.00 | $0.00 |
| YoY Change | ||
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $8.220M | $6.655M |
| Total Long-Term Liabilities | $0.00 | $0.00 |
| Total Liabilities | $8.221M | $6.655M |
| YoY Change | 23.53% | 7.51% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$99.93M | -$94.72M |
| YoY Change | 5.5% | |
| Common Stock | $138.8K | $96.00K |
| YoY Change | 44.6% | |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | -$7.269M | -$5.354M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $951.8K | $1.301M |
| YoY Change | -26.83% | -62.73% |
Cashflow Statement
| Concept | 2017 Q1 | 2016 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$493.5K | -$1.725M |
| YoY Change | -71.38% | 48.78% |
| Depreciation, Depletion And Amortization | $6.120K | $836.00 |
| YoY Change | 632.06% | -9.62% |
| Cash From Operating Activities | -$110.0K | -$1.012M |
| YoY Change | -89.13% | -6.35% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | ||
| YoY Change | ||
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $0.00 | $0.00 |
| YoY Change | ||
| Cash From Investing Activities | $0.00 | $1.000K |
| YoY Change | -100.0% | |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 80.00K | 1.459M |
| YoY Change | -94.52% | |
| NET CHANGE | ||
| Cash From Operating Activities | -110.0K | -1.012M |
| Cash From Investing Activities | 0.000 | 1.000K |
| Cash From Financing Activities | 80.00K | 1.459M |
| Net Change In Cash | -30.00K | 448.2K |
| YoY Change | -106.69% | -141.5% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$110.0K | -$1.012M |
| Capital Expenditures | ||
| Free Cash Flow | ||
| YoY Change |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2017Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
461347 | |
| CY2016Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
455227 | |
| CY2017Q1 | snwv |
Accrued Audit And Tax Preparation
AccruedAuditAndTaxPreparation
|
45000 | |
| CY2016Q4 | snwv |
Accrued Audit And Tax Preparation
AccruedAuditAndTaxPreparation
|
100000 | |
| CY2017Q1 | snwv |
Accrued Board Of Director Fees
AccruedBoardOfDirectorFees
|
32000 | |
| CY2016Q4 | snwv |
Accrued Board Of Director Fees
AccruedBoardOfDirectorFees
|
16000 | |
| CY2017Q1 | snwv |
Accrued Clinical Study Expenses
AccruedClinicalStudyExpenses
|
13650 | |
| CY2016Q4 | snwv |
Accrued Clinical Study Expenses
AccruedClinicalStudyExpenses
|
13650 | |
| CY2017Q1 | snwv |
Accrued Executive Severance
AccruedExecutiveSeverance
|
100000 | |
| CY2016Q4 | snwv |
Accrued Executive Severance
AccruedExecutiveSeverance
|
100000 | |
| CY2017Q1 | snwv |
Accrued Outside Services Current
AccruedOutsideServicesCurrent
|
47615 | |
| CY2016Q4 | snwv |
Accrued Outside Services Current
AccruedOutsideServicesCurrent
|
31533 | |
| CY2017Q1 | snwv |
Class Of Warrant Or Right Change In Fair Value
ClassOfWarrantOrRightChangeInFairValue
|
-323223 | |
| CY2017Q1 | snwv |
Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
|
1966666 | |
| CY2017Q1 | snwv |
Class Of Warrant Or Right Expired During Period
ClassOfWarrantOrRightExpiredDuringPeriod
|
||
| CY2017Q1 | snwv |
Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
|
||
| CY2017Q1 | snwv |
Class Of Warrant Or Right Value Issued During Period
ClassOfWarrantOrRightValueIssuedDuringPeriod
|
||
| CY2017Q1 | snwv |
Class Of Warrant Or Rights Converted During The Period
ClassOfWarrantOrRightsConvertedDuringThePeriod
|
||
| CY2017Q1 | snwv |
Class Or Warrant Or Right Value Of Warrants Converted During The Period
ClassOrWarrantOrRightValueOfWarrantsConvertedDuringThePeriod
|
57372 | |
| CY2017Q1 | snwv |
Gain Loss On Warrant Valuation Adjustment And Conversion
GainLossOnWarrantValuationAdjustmentAndConversion
|
323223 | |
| CY2016Q1 | snwv |
Gain Loss On Warrant Valuation Adjustment And Conversion
GainLossOnWarrantValuationAdjustmentAndConversion
|
-797697 | |
| CY2017Q1 | snwv |
Interest Payable Related Parties Current
InterestPayableRelatedPartiesCurrent
|
246264 | |
| CY2016Q4 | snwv |
Interest Payable Related Parties Current
InterestPayableRelatedPartiesCurrent
|
109426 | |
| CY2016 | snwv |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Forfeiture Rate
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
|
0 | |
| CY2017Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1033341 | |
| CY2016Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
712964 | |
| CY2017Q1 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
451369 | |
| CY2016Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
460799 | |
| CY2017Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
546829 | |
| CY2016Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
375088 | |
| CY2017Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
29184 | |
| CY2016Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
45000 | |
| CY2017Q1 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
30000 | |
| CY2016Q4 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
||
| CY2017Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-50284 | |
| CY2016Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-52069 | |
| CY2017Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
92569540 | |
| CY2016Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
92436697 | |
| CY2017Q1 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
40348 | |
| CY2016Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
35196 | |
| CY2017Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
55900 | |
| CY2016Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
5694 | |
| CY2017Q1 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
||
| CY2016Q1 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
74549 | |
| CY2017Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
||
| CY2016Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
76689 | |
| CY2017Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
92323468 | |
| CY2016Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
62332963 | |
| CY2017Q1 | us-gaap |
Assets
Assets
|
951822 | |
| CY2016Q4 | us-gaap |
Assets
Assets
|
1004870 | |
| CY2017Q1 | us-gaap |
Assets Current
AssetsCurrent
|
867163 | |
| CY2016Q4 | us-gaap |
Assets Current
AssetsCurrent
|
914146 | |
| CY2017Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
97538 | |
| CY2016Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
133571 | |
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
152930 | |
| CY2016Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
604135 | |
| CY2017Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-36033 | |
| CY2016Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
451205 | |
| CY2016Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
78086749 | |
| CY2017Q1 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
76120083 | |
| CY2017Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2016Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2017Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2016Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2016Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2016Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
350000000 | |
| CY2016Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
350000000 | |
| CY2017Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
138815329 | |
| CY2016Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
137219968 | |
| CY2017Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
138815329 | |
| CY2016Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
137219968 | |
| CY2017Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
138815 | |
| CY2016Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
137220 | |
| CY2017Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-491747 | |
| CY2016Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-1721604 | |
| CY2017Q1 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
55144 | |
| CY2016Q1 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
73181 | |
| CY2017Q1 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
49841 | |
| CY2016Q4 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
41341 | |
| CY2017Q1 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
33824 | |
| CY2016Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
18810 | |
| CY2017Q1 | us-gaap |
Deposit Liability Current
DepositLiabilityCurrent
|
158000 | |
| CY2016Q4 | us-gaap |
Deposit Liability Current
DepositLiabilityCurrent
|
||
| CY2017Q1 | us-gaap |
Depreciation
Depreciation
|
6120 | |
| CY2016Q1 | us-gaap |
Depreciation
Depreciation
|
836 | |
| CY2017Q1 | us-gaap |
Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
|
861525 | |
| CY2016Q4 | us-gaap |
Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
|
1242120 | |
| CY2017Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
0 | |
| CY2016Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.02 | |
| CY2017Q1 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
1785 | |
| CY2016Q1 | us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
2972 | |
| CY2017Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
64860 | |
| CY2016Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
64860 | |
| CY2017Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-323223 | |
| CY2016Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
873118 | |
| CY2017Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-3378 | |
| CY2016Q1 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-2980 | |
| CY2017Q1 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
||
| CY2016Q1 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
1000 | |
| CY2017Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
448606 | |
| CY2016Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
499132 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
320377 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-153022 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-4278 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-27370 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
171741 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-107371 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
||
| CY2016Q1 | us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
44613 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
136838 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
-56835 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-29074 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-26413 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
||
| CY2016Q1 | us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
-79948 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
55 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
94 | |
| CY2017Q1 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
27554 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
23530 | |
| CY2017Q1 | us-gaap |
Interest Expense
InterestExpense
|
192738 | |
| CY2016Q1 | us-gaap |
Interest Expense
InterestExpense
|
234430 | |
| CY2017Q1 | us-gaap |
Interest Paid
InterestPaid
|
||
| CY2016Q1 | us-gaap |
Interest Paid
InterestPaid
|
209549 | |
| CY2017Q1 | us-gaap |
Inventory Net
InventoryNet
|
202879 | |
| CY2016Q4 | us-gaap |
Inventory Net
InventoryNet
|
231953 | |
| CY2017Q1 | us-gaap |
Liabilities
Liabilities
|
8220731 | |
| CY2016Q4 | us-gaap |
Liabilities
Liabilities
|
7916470 | |
| CY2017Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
951822 | |
| CY2016Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
1004870 | |
| CY2017Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div> </div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Nature of the Business</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">SANUWAVE Health, Inc. and subsidiaries (the “Company”) is an acoustic shock wave technology company using a patented system of noninvasive, high-energy, acoustic pressure shock waves for regenerative medicine and other applications. The Company’s initial focus is regenerative medicine – utilizing noninvasive (extracorporeal), acoustic shock waves to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal and vascular structures. The Company’s lead regenerative product in the United States is the dermaPACE<div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline; vertical-align: baseline; position: relative; bottom:.33em;">®</div> device, used for treating diabetic foot ulcers, which was subject to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> double-blinded, randomized Phase III clinical studies. The results of these clinical studies were submitted to the U.S. Food and Drug Adminstration (“FDA”) in late <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> after our in-person meeting to discuss the submission strategy, for possible approval in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">second</div> half of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company’s portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body’s normal healing processes and regeneration. The Company intends to apply its Pulsed Acoustic Cellular Expression (PACE<div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline; vertical-align: baseline; position: relative; bottom:.33em;">®</div>) technology in wound healing, orthopedic, plastic/cosmetic and cardiac conditions. The Company currently does not market any commercial products for sale in the United States. Revenues are from sales of the European Conformity Marking (“CE Mark”) devices and accessories in Europe, Canada, Asia and Asia/Pacific. </div></div></div> | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
77066 | |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
1458775 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
||
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
1000 | |
| CY2017Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-114884 | |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-1011542 | |
| CY2017Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-493532 | |
| CY2016 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6439040 | |
| CY2016Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1724576 | |
| CY2017Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
127107 | |
| CY2016Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1035107 | |
| CY2017Q1 | us-gaap |
Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
|
5367912 | |
| CY2016Q4 | us-gaap |
Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
|
5364572 | |
| CY2017Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
715064 | |
| CY2016Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
885612 | |
| CY2017Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-620639 | |
| CY2016Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-689469 | |
| CY2017Q1 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
666956 | |
| CY2017Q1 | us-gaap |
Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
|
148288 | |
| CY2017Q1 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
143969 | |
| CY2017Q1 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
139775 | |
| CY2017Q1 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
135704 | |
| CY2017Q1 | us-gaap |
Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
|
99220 | |
| CY2017Q1 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
33107 | |
| CY2016Q1 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
42519 | |
| CY2017Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
7715 | |
| CY2016Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
8754 | |
| CY2017Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
13841 | |
| CY2016Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
13786 | |
| CY2017Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
1785 | |
| CY2016Q1 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
2972 | |
| CY2016Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q1 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
115377 | |
| CY2016Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
87823 | |
| CY2017Q1 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
||
| CY2016Q1 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
1352775 | |
| CY2017Q1 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
||
| CY2016Q1 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
1000 | |
| CY2017Q1 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
77066 | |
| CY2016Q1 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
||
| CY2017Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
532165 | |
| CY2016Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
532165 | |
| CY2017Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
70818 | |
| CY2016Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
76938 | |
| CY2017Q1 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
5152 | |
| CY2016Q1 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
1052 | |
| CY2017Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
260338 | |
| CY2016Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
309955 | |
| CY2017Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-99926980 | |
| CY2016Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-99433448 | |
| CY2017Q1 | us-gaap |
Revenues
Revenues
|
149569 | |
| CY2016Q1 | us-gaap |
Revenues
Revenues
|
269324 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2017Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
||
| CY2016Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
4500 | |
| CY2016 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
| CY2016 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.011 | |
| CY2016 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
|
1.4 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
16203385 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
0.38 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
0 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
0 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
0 | |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
16203385 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
16203385 | |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
0.38 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
0.38 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2017Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2016 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y | |
| CY2017Q1 | us-gaap |
Short Term Borrowings
ShortTermBorrowings
|
100000 | |
| CY2016Q4 | us-gaap |
Short Term Borrowings
ShortTermBorrowings
|
47440 | |
| CY2016Q3 | us-gaap |
Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
|
435392 | |
| CY2017Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | |
| CY2017Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-7268909 | |
| CY2016Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-6911600 | |
| CY2016Q4 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
1242120 | |
| CY2017Q1 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
861525 | |
| CY2017Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
138042070 | |
| CY2016Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
75220485 |
